|
1
|
Hendriks LEL, Bootsma G, Mourlanette J,
Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J,
Lefebvre C, Duchemann B, et al: Survival of patients with non-small
cell lung cancer having leptomeningeal metastases treated with
immune checkpoint inhibitors. Eur J Cancer. 116:182–189. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gettinger S, Horn L, Jackman D, Spigel D,
Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC,
et al: Five-Year Follow-up of nivolumab in previously treated
advanced non-small-cell lung cancer: Results from the CA209-003
study. J Clin Oncol. 36:1675–1684. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyero L, Sanchez-Palencia A, Miranda-Leon
MT, Hernandez-Escobar F, Gomez-Capilla JA and Farez-Vidal ME:
Survival, classifications, and desmosomal plaque genes in non-small
cell lung cancer. Int J Med Sci. 10:1166–1173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaoyan X, Juanjuan Y, Yalan T, Ping H,
Jianzhong L and Qinian W: Downregulation of EIF4A2 in
non-small-cell lung cancer associates with poor prognosis. Clin
Lung Cancer. 14:658–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vendetti FP and Rudin CM: Epigenetic
therapy in non-small-cell lung cancer: Targeting DNA
methyltransferases and histone deacetylases. Expert Opin Biol Ther.
13:1273–1285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caporali A and Emanueli C: MicroRNA
regulation in angiogenesis. Vascular Pharmacol. 55:79–86. 2011.
View Article : Google Scholar
|
|
7
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu SL, Chen HY, Chang GC, Chen CY, Chen
HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al: MicroRNA
signature predicts survival and relapse in lung cancer. Cancer
Cell. 13:48–57. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Tan G, Dong L, Cheng L, Li K, Wang
Z and Luo H: Circulating MiR-125b as a marker predicting
chemoresistance in breast cancer. PLoS One. 7:e342102012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang Z, Li Y, Huang K, Wagar N and Shim
H: Regulation of miR-19 to breast cancer chemoresistance through
targeting PTEN. Pharm Res. 28:3091–3100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z,
Chen K, He J and Su F: Plasma miR-221 as a predictive biomarker for
chemoresistance in breast cancer patients who previously received
neoadjuvant chemotherapy. Onkologie. 34:675–680. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ke Y, Zhao W, Xiong J and Cao R: miR-149
inhibits non-small-cell lung cancer Cells EMT by targeting FOXM1.
Biochem Res Int. 2013:5067312013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G III, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Min X, Wen J, Zhao L, Wang K, Li Q, Huang
G, Liu J and Zhao X: Role of hepatoma-derived growth factor in
promoting de novo lipogenesis and tumorigenesis in hepatocellular
carcinoma. Mol Oncol. 12:1480–1497. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu TH, Huang CC, Liu LF, Lin PR, Liu SY,
Chang HW, Changchien CS, Lee CM, Chuang JH and Tai MH: Expression
of hepatoma-derived growth factor in hepatocellular carcinoma.
Cancer. 98:1444–1456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamamoto S, Tomita Y, Hoshida Y, Takiguchi
S, Fujiwara Y, Yasuda T, Doki Y, Yoshida K, Aozasa K, Nakamura H
and Monden M: Expression of hepatoma-derived growth factor is
correlated with lymph node metastasis and prognosis of gastric
carcinoma. Clin Cancer Res. 12:117–122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren H, Chu Z and Mao L: Antibodies
targeting hepatoma-derived growth factor as a novel strategy in
treating lung cancer. Mol Cancer Ther. 8:1106–1112. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Enomoto H, Nakamura H, Liu W and
Nishiguchi S: Hepatoma-derived growth factor: Its possible
involvement in the progression of hepatocellular carcinoma. Int J
Mol Sci. 16:14086–14097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang D, Qiu C, Zhang H, Wang J, Cui Q and
Yin Y: Human microRNA oncogenes and tumor suppressors show
significantly different biological patterns: From functions to
targets. PLoS One. 5(pii): e130672010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu T, Ma P, Wu D, Shu Y and Gao W:
Functions and mechanisms of microRNA-31 in human cancers. Biomed
Pharmacother. 108:1162–1169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guraya S: Prognostic significance of
circulating microRNA-21 expression in esophageal, pancreatic and
colorectal cancers; a systematic review and meta-analysis. Int J
Surg. 60:41–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iqbal MA, Arora S, Prakasam G, Calin GA
and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways
and therapeutic relevance. Mol Aspects Med. 70:3–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karmakar S, Kaushik G, Nimmakayala R,
Rachagani S, Ponnusamy MP and Batra SK: MicroRNA regulation of
K-Ras in pancreatic cancer and opportunities for therapeutic
intervention. Semin Cancer Biol. 54:63–71. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang J, Liu H, Wang H and Sun Y:
Down-regulation of microRNA-181b is a potential prognostic marker
of non-small cell lung cancer. Pathol Res Pract. 209:490–494. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS
Lett. 587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma Q, Wang X, Li Z, Li B, Ma F, Peng L,
Zhang Y, Xu A and Jiang B: microRNA-16 represses colorectal cancer
cell growth in vitro by regulating the p53/survivin
signaling pathway. Oncol Rep. 29:1652–1658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li SZ, Zhao YB, Cao WD, Qu Y, Luo P, Zhen
HN, Chen XY, Yan ZF and Fei Z: The expression of hepatoma-derived
growth factor in primary central nervous system lymphoma and its
correlation with angiogenesis, proliferation and clinical outcome.
Med Oncol. 30:6222013. View Article : Google Scholar : PubMed/NCBI
|
